CCA
ABBV icon

Carrera Capital Advisors’s AbbVie ABBV Stock Holding History

Carrera Capital Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,348
Closed -$282K – 144
2025
Q1 		$282K Buy
1,348
+153
+13% +$29.7K 0.06% 133
2024
Q4 		$212K Sell
1,195
-11,285
-90% -$2.07M 0.05% 129
2024
Q3 		$2.46M Buy
12,480
+2,094
+20% +$391K 0.6% 31
2024
Q2 		$1.78M Buy
+10,386
New +$1.72M 0.58% 31

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Carrera Capital Advisors's ABBV Position: Q2 2025 in Review

Carrera Capital Advisors sold out of AbbVie (ABBV) in Q2 2025, closing a stake of 1,348 shares — an estimated $282K sold.

Carrera Capital Advisors first reported a position in ABBV in Q2 2024 and held it in 4 quarters. The position peaked at $2.46M in Q3 2024. 3,781 funds tracked by Wall St. Rank hold ABBV as of Q2 2025.

  • Carrera Capital Advisors reported no remaining AbbVie position as of Q2 2025 after selling out during the quarter.
  • Carrera Capital Advisors sold 1,348 AbbVie shares in Q2 2025, an estimated $282K.
  • Carrera Capital Advisors first reported a position in AbbVie in Q2 2024 and held it in 4 quarters.
  • Carrera Capital Advisors's AbbVie position peaked at $2.46M in Q3 2024.
  • 3,781 funds tracked by Wall St. Rank held AbbVie as of Q2 2025.

Based on Carrera Capital Advisors's 13F filing for Q2 2025, filed 31 Jul 2025.